# Alloy Therapeutics, Inc.

> Alloy Therapeutics is a biotechnology ecosystem company that democratizes access to the tools, platforms, and expertise needed to discover and develop new drugs. Founded in 2017 by Errik Anderson and headquartered in the Boston area (Lexington, Massachusetts), Alloy gives more than 200 partners non-exclusive, affordable access to proprietary technologies - led by its royalty-free ATX-Gx transgenic-mouse antibody discovery platform - along with discovery services and a venture studio that builds new biotech companies. Its model is unusual: Alloy reinvests revenue into innovation and its controlling stock cannot be sold. In April 2026 the company raised a $40M Series E at a $1B valuation.

- **Founded:** 2017
- **Headquarters:** Lexington, Massachusetts, United States
- **Founders:** Errik Anderson (Founder, CEO & Chairman)
- **Team size:** ~150 employees
- **Products:** ATX-Gx Antibody Discovery Platform, mAbForge, Keyway TCR Discovery, Genetic Medicines & Cell Therapy Services, Discovery Services (CRO)
- **Notable:** Reached a $1B valuation with its April 2026 Series E while remaining private., Built ATX-Gx into the world's first royalty-free in vivo human antibody discovery platform, now used by 170+ partners., Grew to 200+ partners and 100+ licensed therapeutic programs.

## Products & services

- **ATX-Gx Antibody Discovery Platform** — A royalty-free suite of immunocompetent transgenic mouse strains engineered to express human antibody genes for best-in-class in vivo fully human antibody discovery. Launched in 2019, it became the first royalty-free in vivo human therapeutic antibody discovery platform and is now used by 170+ partners.
- **mAbForge** — A rapid make-test high-throughput screening service that lets partners screen antibody sequences in roughly three weeks.
- **Keyway TCR Discovery** — An integrated T-cell receptor discovery platform for TCR mimics and cell-therapy programs, launched in 2022.
- **Genetic Medicines & Cell Therapy Services** — Discovery and development services spanning antisense oligonucleotides (ASOs), genetic medicines, and cell therapies.
- **Discovery Services (CRO)** — Contract research services running end-to-end drug discovery campaigns across antibodies, bispecifics, peptides, and drug delivery, increasingly powered by AI/ML.
- **82VS Venture Studio** — A company-creation engine that provides capital, expertise, and shared infrastructure to entrepreneurs building new biotech companies.

## Achievements

- Reached a $1B valuation with its April 2026 Series E while remaining private.
- Built ATX-Gx into the world's first royalty-free in vivo human antibody discovery platform, now used by 170+ partners.
- Grew to 200+ partners and 100+ licensed therapeutic programs.
- Advanced 22 programs into clinical development, including two drugs in Phase 3.
- Reportedly no company that licensed its technology has failed.
- Signed a multi-year antibody-platform collaboration with Pfizer.

## Latest updates

- **2026-04** — Closed a $40M Series E at a $1B valuation to scale its tech-enabled, AI-driven biotech infrastructure.
- **2026-03** — Entered an agreement to advance a novel antibody discovery platform.
- **2025-02** — Established a multi-year collaboration with Pfizer to develop a new antibody discovery platform.
- **2024-10** — Signed an institutional ATX-Gx license with Scripps Research and launched a new royalty-free licensing model plus the mAbForge screening service.

## Links

- Website: https://alloytx.com
- LinkedIn: http://www.linkedin.com/company/alloy-therapeutics-inc
- Twitter/X: https://twitter.com/alloytx

---

Profile page: https://yespress.io/alloy-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-10